Eric Richman

Develops bio therapeutics to address biological pathogens and chemicals

State chartered commercial bank

Develops medicines for treatment of infectious diseases

Functions as a College/University

Offers drug discovery and development focused on small molecule kinase inhibitors

Brace Pharmaceuticals invests in companies located in the United States and Brazil. The firm targets companies operating in the fields of bio-pharmaceuticals and biotech. It provides financing for early and late stage capital requirements.

Provides health care services

Develops peptide-nucleic acid antisense oligonucleotide platform

Allele Capital Partners invests in both public and private companies located in the United States. The firm focuses on a broad range of sectors and industries. It provides debt and equity financing for growth stage capital requirements.

Operates as a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders

Owns and operates ambulatory infusion centers

Operates as biotechnology company

Provides central laboratory support services

Specializes in development of anti-tumor immune redirection therapy targeting cancer using pre-existing immune memory

F2g Inc. is a biopharmaceutical and biotechnology company specializing in the discovery and development of novel antifungal therapies targeting rare, life-threatening fungal infections. The company is based in Princeton, NJ. The company leverages proprietary genomic and molecular biology technologies to develop small-molecule inhibitors, such as orotomides, which selectively inhibit fungal dihydroorotate dehydrogenase (dhodh), a key enzyme essential for fungal DNA, RNA, and protein synthesis. This mechanism induces fungal cell death and differs from existing antifungals that primarily inhibit fungal growth. The company's lead drug candidate, olorofim, targets invasive fungal infections such as invasive aspergillosis and coccidioidomycosis (valley fever), addressing unmet medical needs related to antifungal resistance, immunosuppressant use, and climate change. F2g’s pipeline includes oral and other formulations for rare, highly resistant mold infections affecting immunocompromised patients. The company offers an early access program for investigational therapies and maintains transparency through media updates, investor communications, and detailed information on its leadership, governance, scientific research, and the fungal disease landscape.